Cara Therapeutics to Present at 3rd Conference on the Therapeutic Potential of Kappa Opioids
April 15 2015 - 7:00AM
- Company to present data from human abuse liability (HAL) study
of I.V. CR845
Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company
focused on developing and commercializing new chemical entities
designed to alleviate pain and pruritus by selectively targeting
kappa opioid receptors, today announced that Chief Medical Officer
Dr. Joseph Stauffer will present data from Cara's human abuse
liability (HAL) study of I.V. CR845 in an oral session at the 3rd
Conference on the Therapeutic Potential of Kappa Opioids, held in
Chapel Hill, North Carolina. CR845 is the Company's first-in-class
peripherally-selective kappa opioid agonist, which has potential to
be the only non-scheduled or Schedule V opioid for acute pain.
The presentation details are as follows:
Title: "CR845, a novel peripherally-acting
kappa opioid receptor agonist, has low abuse potential compared
with pentazocine" Date: Wednesday, April 22, 2015
Time: 9:15 a.m. ET Location: The
Carolina Inn, Chapel Hill, North Carolina Speaker:
Joseph Stauffer, DO, MBA
For more information about the 3rd Conference on the Therapeutic
Potential of Kappa Opioids, please visit
http://depts.washington.edu/nidactr/kappatherapeutics2015.html.
About CR845
CR845 is a peripherally acting kappa opioid receptor agonist
currently in development for the treatment of acute and chronic
pain and uremic pruritus. In multiple randomized, double blind,
placebo-controlled Phase 2 trials in patients undergoing
laparoscopic hysterectomy or bunionectomy procedures, I.V. CR845
treatment resulted in statistically significant reductions in pain
intensity and opioid-related side effects. In over 400 subjects
dosed to date, I.V. CR845 was found to be safe and well tolerated,
without incurring the dysphoric and psychotomimetic side effects
that have been reported with centrally acting (CNS-active) kappa
opioid receptor agonists. In a human abuse liability trial, I.V.
CR845 met the primary endpoint showing highly statistically
significant reductions (p < 0.0001) in scores for "drug liking,"
as well as "feeling high," "overall liking," and "take drug again"
when compared to I.V. pentazocine, a Schedule IV opioid
analgesic.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biotechnology company
focused on developing and commercializing new chemical entities
designed to alleviate pain and pruritus by selectively targeting
kappa opioid receptors. Cara is developing a novel and proprietary
class of product candidates that target the body's peripheral
nervous system and have demonstrated efficacy in patients with
moderate-to-severe pain without inducing many of the undesirable
side effects typically associated with currently available pain
therapeutics.
CONTACT: INVESTOR CONTACT:
Jesse Baumgartner
Stern Investor Relations, Inc.
212-362-1200
Jesse@sternir.com
MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
astarr@6degreespr.com
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Jul 2023 to Jul 2024